.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB07_InterferonBeta1a.InterferonBeta1a

Information

Interferon beta-1a is a recombinant form of human interferon beta, used primarily in the treatment of relapsing forms of multiple sclerosis (MS). It is approved by regulatory agencies such as the FDA and EMA for MS to reduce frequency of relapses and slow progression of physical disability.

Pharmacokinetics

Pharmacokinetics reported for healthy volunteers and MS patients after single subcutaneous or intramuscular administration.

References

1. David, OJ, et al., & Schmouder, RL (2012). Clinical pharmacokinetics of fingolimod. Clinical pharmacokinetics 51(1) 15–28. DOI:10.2165/11596550-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149256

2. Saida, T, et al., & Hao, Q (2012). Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions. Multiple sclerosis (Houndmills, Basingstoke, England) 18(12) 1782–1790. DOI:10.1177/1352458512442261 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22492130

3. Rogge, MC, et al., & Galluppi, GR (2014). Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent. Journal of clinical pharmacology 54(10) 1153–1161. DOI:10.1002/jcph.311 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24737408

Revisions

• 06/2025 initial generated model